Biodistribution and pharmacokinetics of recombinant, human 125I-interleukin-2 in mice.
The pharmacokinetics and biodistribution of radioiodinated recombinant interleukin-2 (125I-IL-2) was studied after either intravenous (i.v.) or intraperitoneal (i.p.) injection into C57BL/6 mice. Beta-lactoglobulin radiolabeled with 131I served as a control protein. After i.v. injection, 125I-IL-2 preferentially accumulated in the liver and spleen. Liver accumulation was fast, peaking at 5 min, and was followed by rapid clearance. Spleen accumulation was slightly slower, peaking at 15 min. Blood values 1 min after i.v. injection were 22-34% of the injected doses (I.D.)/gram. These values declined quickly over the next hour. In contrast, after i.p. administration no organ showed specific uptake of 125I-IL-2. Blood values after i.p. injection were essentially constant over 3 h and were greater and more sustained than after i.v. administration. Kidney values for both 125I-IL-2 and 131I-beta-lactoglobulin, after either i.v. or i.p. injection, indicated that the major route of clearance for both compounds was rapid loss through the kidneys.
Sands
H
H
E. I. duPont deNemours and Company, Inc., Medical Products Department Immunopharmaceuticals Research, Billerica, MA 01862.
Loveless
S E
SE
D000818:Animals; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage / Q000493:pharmacokinetics*; D007457:Iodine Radioisotopes; D007782:Lactoglobulins / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000493:pharmacokinetics; D014018:Tissue Distribution
D007376:Interleukin-2; D007457:Iodine Radioisotopes; D007782:Lactoglobulins; D011994:Recombinant Proteins